Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Passes Above 200 Day Moving Average - Should You Sell?

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL - Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $6.36. Cryo-Cell International shares last traded at $6.33, with a volume of 5,900 shares traded.

Wall Street Analysts Forecast Growth

Separately, Maxim Group lowered their price objective on Cryo-Cell International from $9.00 to $8.50 and set a "buy" rating for the company in a research note on Tuesday, March 4th.

Cryo-Cell International Stock Down 4.0 %

The company has a market cap of $42.48 million, a price-to-earnings ratio of -4.97 and a beta of 0.53.

Cryo-Cell International Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Friday, February 14th were issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 18.98%. The ex-dividend date was Friday, February 14th. Cryo-Cell International's dividend payout ratio (DPR) is presently -94.34%.

Hedge Funds Weigh In On Cryo-Cell International

Several institutional investors have recently modified their holdings of CCEL. Rowlandmiller & PARTNERS.ADV purchased a new stake in Cryo-Cell International during the fourth quarter worth about $107,000. CreativeOne Wealth LLC bought a new position in shares of Cryo-Cell International during the 4th quarter valued at approximately $113,000. Heron Bay Capital Management purchased a new stake in shares of Cryo-Cell International during the 4th quarter worth approximately $235,000. Geode Capital Management LLC raised its holdings in shares of Cryo-Cell International by 68.5% in the 3rd quarter. Geode Capital Management LLC now owns 39,860 shares of the company's stock worth $254,000 after purchasing an additional 16,203 shares during the period. Finally, Northern Trust Corp lifted its stake in Cryo-Cell International by 78.2% in the fourth quarter. Northern Trust Corp now owns 38,902 shares of the company's stock valued at $288,000 after purchasing an additional 17,066 shares during the last quarter. 10.44% of the stock is owned by institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.